A Phase I trial evaluating mucosal administration of a candidate TB vaccine, MVA85A, as a way to induce potent local cellular immune responses and avoid anti-vector immunity

Trial Profile

A Phase I trial evaluating mucosal administration of a candidate TB vaccine, MVA85A, as a way to induce potent local cellular immune responses and avoid anti-vector immunity

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs MVA 85A (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions
  • Acronyms TB035
  • Most Recent Events

    • 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
    • 27 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 04 Sep 2015 Accrual to date is 102% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top